Roche Pharmaceutical Development and Sales Overview
Al submissions for existing products
Projects in phase II and III
RG6264
Phesgo OBI
HER2+ BC
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other
Roche
RG6396
Gavreto
Tumor agnostic (US)
Tecentriq + cabozantinib
RG7446
2L NSCLC
Kadcyla + Tecentriq
RG3502
2L+ HER-2+ PD-L1+ mBC
RG3502
Kadcyla + Tecentriq
HER-2+ eBC high-risk
Tecentriq + cabozantinib
RG7446
RG7446
RCC adv
Tecentriq + Avastin
RG7446
RG7446
HCC adj
RG6413+
Ronapreve**
RG7446
RG6412
SARS-CoV-2 hospitalized (EU)✓
Tecentriq²
NSCLC periadj
RG1594
Ocrevus SC
RMS & PPMS
RG7446
Tecentriq + paclitaxel
TNBC adj
RG7159
Actemra
RG1569
RG7446
COVID-19 pneumonia¹ ✓
Tecentriq
SCCHN adj
TNKase
Tecentriq
RG3625
RG7446
RG7159
stroke
ctDNA+ high-risk MIBC
Tecentriq
High risk NMIBC
Tecentriq+ lurbinectedin
1l maintenance SCLC
Gazyva
Gazyva
systemic lupus
erythematosus
membranous nephropathy
Tecentriq ± chemo
Venclexta
RG7446
RG7601
RG3648
1L MUC
r/r MM t(11:14)
Xolair
food allergy
RG7601
Venclexta + azacitidine
1L MDS
Ocrevus higher dose
RG1594
Tecentriq + capecitabine
RG7446
Tecentriq SC
2L NSCLC
RG7446
or carbo/gem
RG6152
Xofluza
direct transmission
RG7159
Gazyva
lupus nephritis
RG6168
TNBC
Xofluza
RG7596
Polivy
1L DLBCL (US)✓
Alecensa
RG7853
RG6152
ALK+ NSCLC adj
influenza, pediatric
(0-1 year)
RG6168
Enspryng
myasthenia gravis
RMS & PPMS
Enspryng
MOG-AD
Enspryng
RG6168
autoimmune encephalitis
2022
2023
2024
2025 and beyond
Status as of October 18, 2022
Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
1Approved in EU, filed in US
2filing timeline based on data from interim analysis
PDS-Port Delivery System with ranibizumab
OBI-On-Body Delivery System
**Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with
Regeneron Pharmaceuticals
56View entire presentation